Rufinamide
Rufinamide is an oral suspension medication containing 40 mg/mL of rufinamide, used to treat seizures associated with Lennox-Gastaut syndrome. Manufactured by Aurobindo Pharma Limited under ANDA216549, it's available as a prescription drug in 460 mL bottles. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[ "009:10" ] |
| contactPoint |
{ "fn": "Division of Drug Information", "@type": "vcard:Contact", "hasEmail": "mailto:druginfo@fda.hhs.gov" } |
| description | Rufinamide is an oral suspension medication containing 40 mg/mL of rufinamide, used to treat seizures associated with Lennox-Gastaut syndrome. Manufactured by Aurobindo Pharma Limited under ANDA216549, it's available as a prescription drug in 460 mL bottles. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[ { "@type": "dcat:Distribution", "title": "Rufinamide", "mediaType": "text/html", "description": " Access the FDA dataset for Rufinamide — ANDA 205075 submitted by Mylan Institutional LLC ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205075" } ] |
| identifier | ANDA205075 |
| issued | 2016-09-16 |
| keyword |
[ "drug", "drug-safety", "medications", "pharmaceuticals", "public-health" ] |
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[ "009:002" ] |
| publisher |
{ "name": "U.S. Food and Drug Administration", "@type": "org:Organization" } |
| theme |
[ "FDA" ] |
| title | Rufinamide |
